MK-2870-015
A Study to Evaluate Sacituzumab Tirumotecan in Advanced/Metastatic Gastroesophageal Adenocarcinoma
Active, Not Recruiting
Trial Purpose
This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician’s choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumotecan is superior to TPC with respect to Overall Survival (OS).
View full trial information on Clinicaltrials.gov|
|
National Trial Reference Number | NCT06356311 |
|
|
MSD Protocol ID |
MK-2870-015 |
|
|
Conditions |
Gastroesophageal Cancer |
|
|
Age Range |
18+ |
|
|
Sex | ALL |
|
|
Trial Phase | 3 |
|
|
Start Date End Date |
2024-05-03 2027-05-06 |
Study Details
Patient Participation
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial.
Conditions
Gastroesophageal Cancer
Trial Phase 3
In Phase 3 trials, researchers try to find out if a treatment works in a large number of people, usually about 1,000 to 5,000 participantsResearch participantIn clinical research, a person who qualifies and agrees to participate in a study. Also called volunteer, trial participant. who have the health condition the treatment is intended to treat. In vaccine trials, the participants may be healthy or have diseases or conditions. Phase 3 trials may happen in a doctor’s office, a clinic, or a hospital.
Trial Locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.
Sorry, there are no locations found.
What can you do next?
If you think this clinical trial might be a good fir and you are interested in taking part, take the next step to see if you are eligible.
Discuss with your doctor or care team
Print this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.






